In addition, UALCAN program analysis also showed that the expression of LINC01615 in diverse cancer types such as bladder carcinoma (BLCA), head and neck squamous cell carcinoma (HNSC), and sarcoma (SARC) was notably upregulated (Figure 6B). Here, LINC01615 is linked to urinary bladder carcinoma.